|Mr. Mark Joseph Enyedy||Pres, CEO & Director||1.21M||N/A||1964|
|Ms. Susan Altschuller Ph.D.||Sr. VP & CFO||391.21k||N/A||1982|
|Dr. Theresa G. Wingrove||Sr. VP of Regulatory Affairs & Quality||548.21k||N/A||1958|
|Dr. Anna Berkenblit||Sr. VP & Chief Medical Officer||641.74k||N/A||1970|
|Ms. Stacy A. Coen||Sr. VP & Chief Bus. Officer||388.97k||N/A||1971|
|Ms. Renee Lentini||VP of Fin., Principal Accounting Officer & Corp. Controller||N/A||N/A||1978|
|Dr. Thomas Ryll||Sr. VP of Technical Operations||N/A||N/A||1961|
|Ms. Courtney O'Konek||Sr. Director of Corp. Communications & Investor Relations||N/A||N/A||N/A|
|Ms. Audrey Bergan||VP & Chief HR Officer||N/A||N/A||N/A|
|Mr. Joseph J. Kenny||Sec.||N/A||N/A||N/A|
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
ImmunoGen, Inc.’s ISS governance QualityScore as of 1 June 2021 is 5. The pillar scores are Audit: 5; Board: 5; Shareholder rights: 5; Compensation: 7.